FR21C1017I2 - Procédés et compositions à base de conjugués de toxine interleukine 3 de diphtérie - Google Patents

Procédés et compositions à base de conjugués de toxine interleukine 3 de diphtérie

Info

Publication number
FR21C1017I2
FR21C1017I2 FR21C1017C FR21C1017C FR21C1017I2 FR 21C1017 I2 FR21C1017 I2 FR 21C1017I2 FR 21C1017 C FR21C1017 C FR 21C1017C FR 21C1017 C FR21C1017 C FR 21C1017C FR 21C1017 I2 FR21C1017 I2 FR 21C1017I2
Authority
FR
France
Prior art keywords
diphtheria
interleukin
compositions
toxin conjugate
conjugate methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR21C1017C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scott and White Memorial Hospital
Original Assignee
Scott and White Memorial Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scott and White Memorial Hospital filed Critical Scott and White Memorial Hospital
Publication of FR21C1017I1 publication Critical patent/FR21C1017I1/fr
Application granted granted Critical
Publication of FR21C1017I2 publication Critical patent/FR21C1017I2/fr
Active legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5403IL-3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/202IL-3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/55Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR21C1017C 2006-09-07 2021-05-11 Procédés et compositions à base de conjugués de toxine interleukine 3 de diphtérie Active FR21C1017I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US84347106P 2006-09-07 2006-09-07
US93277207P 2007-06-01 2007-06-01
PCT/US2007/019481 WO2008030539A2 (en) 2006-09-07 2007-09-07 Methods and compositions based on diphtheria toxin-interleukin-3 conjugates
EP07837840.3A EP2063907B1 (en) 2006-09-07 2007-09-07 Methods and compositions based on diphtheria toxin-interleukin-3 conjugates

Publications (2)

Publication Number Publication Date
FR21C1017I1 FR21C1017I1 (ja) 2021-07-02
FR21C1017I2 true FR21C1017I2 (fr) 2022-04-22

Family

ID=39157851

Family Applications (1)

Application Number Title Priority Date Filing Date
FR21C1017C Active FR21C1017I2 (fr) 2006-09-07 2021-05-11 Procédés et compositions à base de conjugués de toxine interleukine 3 de diphtérie

Country Status (17)

Country Link
US (7) US7763242B2 (ja)
EP (3) EP3207941B3 (ja)
JP (7) JP5550905B2 (ja)
AU (1) AU2007293047B2 (ja)
CA (5) CA2698595C (ja)
CY (2) CY1119654T1 (ja)
DK (2) DK2063907T3 (ja)
ES (2) ES2646545T3 (ja)
FR (1) FR21C1017I2 (ja)
HU (2) HUE048356T2 (ja)
LT (2) LT3207941T (ja)
LU (1) LUC00206I2 (ja)
NL (1) NL301103I2 (ja)
PL (2) PL2063907T3 (ja)
PT (1) PT3207941T (ja)
SI (1) SI3207941T1 (ja)
WO (1) WO2008030539A2 (ja)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1692113T3 (en) 2003-11-14 2018-01-08 Lorus Therapeutics Inc ARYLIMIDAZOLES AND USE THEREOF AS ANTICANCES
EP3207941B3 (en) 2006-09-07 2020-08-19 Scott & White Memorial Hospital Methods and compositions based on diphtheria toxin-interleukin-3 conjugates
WO2010027802A2 (en) 2008-08-25 2010-03-11 New York University Methods for treating diabetic wounds
US20110171219A1 (en) * 2008-09-19 2011-07-14 Fahar Merchant Treating cancer stem cells using targeted cargo proteins
NZ601760A (en) * 2010-02-17 2013-10-25 Csl Ltd Compositions and methods for targeting type 1 interferon producing cells
US9254310B2 (en) 2010-06-17 2016-02-09 New York University Therapeutic and cosmetic uses and applications of calreticulin
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
SG10201506782XA (en) 2010-08-27 2015-10-29 Stem Centrx Inc Notum protein modulators and methods of use
CN106620693A (zh) 2010-09-03 2017-05-10 艾伯维施特姆森特克斯有限责任公司 新型调节剂及使用方法
RU2592672C9 (ru) 2010-12-08 2016-11-27 СтемСентРкс, Инк. Новые модуляторы и способы их применения
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
CA2840989A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
SG10201801444WA (en) 2012-02-24 2018-04-27 Abbvie Stemcentrx Llc Anti sez6 antibodies and methods of use
WO2013126746A2 (en) 2012-02-24 2013-08-29 Stem Centrx, Inc. Novel modulators and methods of use
CN105164159A (zh) 2013-02-22 2015-12-16 施特姆森特克斯股份有限公司 新的抗体缀合物及其用途
KR20160046914A (ko) 2013-08-28 2016-04-29 스템센트알엑스 인코포레이티드 신규한 sez6 조절물질 및 사용방법
CN105848671B (zh) 2013-08-28 2019-12-13 艾伯维施特姆森特克斯有限责任公司 位点特异性抗体缀合方法和组合物
WO2015051302A1 (en) 2013-10-04 2015-04-09 Aptose Biosciences Inc. Compositions and methods for treating cancers
PE20160870A1 (es) 2013-11-06 2016-09-09 Abbvie Stemcentrx Llc Anticuerpos anti-claudina novedosos y metodos de uso
CN106104273A (zh) 2013-12-12 2016-11-09 施特姆森特克斯股份有限公司 新型抗dpep3抗体和使用方法
MX2016010677A (es) 2014-02-21 2017-04-10 Abbvie Stemcentrx Llc Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma.
PL3137114T3 (pl) 2014-04-30 2021-06-28 Pfizer Inc. Koniugaty przeciwciało anty-ptk7-lek
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗mfi2抗體及使用方法
AU2017254674A1 (en) 2016-04-21 2018-11-01 Abbvie Stemcentrx Llc Novel anti-BMPR1B antibodies and methods of use
CN107793481A (zh) * 2016-08-31 2018-03-13 南京传奇生物科技有限公司 一种靶向人cd123的嵌合受体配体及其应用
JP2021501203A (ja) 2017-10-30 2021-01-14 アプトース バイオサイエンシズ インコーポレイテッド がん治療用のアリールイミダゾール
WO2019210179A1 (en) 2018-04-27 2019-10-31 Stemline Therapeutics, Inc. Methods of treating an autoimmune disease with a human interleukin-3 (il-3)-diphtheria toxin conjugate (dt-il3)
WO2019227222A1 (en) * 2018-05-30 2019-12-05 The Governing Council Of The University Of Toronto Methods and kits for identifying a protein associated with receptor-ligand interactions
BR112021007945A2 (pt) * 2018-10-31 2021-08-03 Stemline Therapeutics, Inc. método de terapia de combinação para tratar neoplasmas mieloproliferativos com um conjugado de toxina de difteria-interleucina-3 humana em combinação com outros agentes
WO2020112642A1 (en) 2018-11-30 2020-06-04 Stemline Therapeutics, Inc. Improved methods of treating myeloproliferative neoplasms with a diphtheria toxin-human interleukin-3 conjugate
WO2021099573A1 (en) * 2019-11-21 2021-05-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for diagnosing and treating chronic myelomonocytic leukemia (cmml)
MX2023006805A (es) 2020-12-10 2023-07-06 Stemline Therapeutics Inc Formulacion liofilizada mejorada.

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3369466D1 (en) 1982-05-12 1987-03-05 Harvard College Fused genes encoding hybrid proteins, cloning vectors containing them and the use thereof
US5080898A (en) 1982-05-12 1992-01-14 The University Hospital Enzymatically active toxin coupled to a cell-specific ligand
US5668255A (en) 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US6022950A (en) 1984-06-07 2000-02-08 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
CA2071867A1 (en) 1989-11-06 1991-05-07 Edith Mathiowitz Method for producing protein microspheres
DE69132581T3 (de) 1990-03-02 2008-07-17 Boston Medical Center Corp., Boston Verbesserte chimäre toxine
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
DE4121547A1 (de) 1991-06-28 1993-01-14 Daimler Benz Ag Mehrschichtisolierfolie
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
DE4140121C2 (de) 1991-12-05 1994-06-30 Manfred Mueller Verfahren zum Herstellen von gefaßten, gegossenen Schmuckstücken
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5441050A (en) 1992-12-18 1995-08-15 Neoprobe Corporation Radiation responsive surgical instrument
WO1996038571A2 (en) * 1995-05-31 1996-12-05 Regents Of The University Of Minnesota Recombinant polypeptide cytotoxins for cancer treatment
EP0850051A2 (en) 1995-08-31 1998-07-01 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
US5843633A (en) 1996-04-26 1998-12-01 Amcell Corporation Characterization of a human hematopoietic progenitor cell antigen
US20040013664A1 (en) 1997-01-14 2004-01-22 Gentz Reiner L. Tumor necrosis factor receptors 6 alpha & 6 beta
US6004528A (en) 1997-09-18 1999-12-21 Bergstein; Ivan Methods of cancer diagnosis and therapy targeted against the cancer stemline
US7361336B1 (en) 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
US7030228B1 (en) 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
WO2001040308A1 (en) 1999-12-03 2001-06-07 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland Dendritic cell-specific antibodies
ATE510855T1 (de) 2000-03-06 2011-06-15 Univ Kentucky Res Found Verwendung eines antikörpers oder eines immunotoxins, der bzw. das selektiv an cd123 bindet zur beeinträchtigung hämatologischer krebs-vorläuferzellen
MXPA03007878A (es) 2001-03-02 2004-07-08 Medimmune Inc Metodos de prevencion o tratamiento de alteraciones inflamatorias o autoinmunes mediante la administracion de los antagonistas alfav, beta3 de integrina.
US20030044406A1 (en) 2001-03-02 2003-03-06 Christine Dingivan Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents
KR20120035234A (ko) 2003-04-11 2012-04-13 메디뮨 엘엘씨 재조합 il?9 항체 및 그의 용도
AU2014201901B2 (en) 2006-09-07 2016-05-05 Scott & White Healthcare Methods and compositions based on diphtheria toxin-interleukin-3 conjugates
EP3207941B3 (en) 2006-09-07 2020-08-19 Scott & White Memorial Hospital Methods and compositions based on diphtheria toxin-interleukin-3 conjugates
US8163279B2 (en) 2007-04-13 2012-04-24 Stemline Therapeutics, Inc. IL3Rα antibody conjugates and uses thereof
EP2820030A4 (en) 2012-02-29 2015-04-15 Ambrx Inc INTERLEUKIN-3-POLYPEPTIDE CONJUGATES AND ITS USES

Also Published As

Publication number Publication date
JP2022065089A (ja) 2022-04-26
CA3053981C (en) 2022-07-12
CA2698595C (en) 2016-07-26
WO2008030539A2 (en) 2008-03-13
US20160024167A1 (en) 2016-01-28
PL3207941T6 (pl) 2020-11-16
AU2007293047A1 (en) 2008-03-13
PL3207941T3 (pl) 2020-07-27
WO2008030539A3 (en) 2009-04-09
EP3207941B1 (en) 2019-12-25
CA3153438C (en) 2024-03-12
US11130792B2 (en) 2021-09-28
DK2063907T3 (da) 2017-11-13
EP3207941A1 (en) 2017-08-23
US20190169251A1 (en) 2019-06-06
US7763242B2 (en) 2010-07-27
CA3007075C (en) 2019-10-15
US9631006B2 (en) 2017-04-25
CA3153438A1 (en) 2008-03-13
JP2020079260A (ja) 2020-05-28
US20080138313A1 (en) 2008-06-12
JP2010502712A (ja) 2010-01-28
LTPA2021507I1 (ja) 2021-06-10
JP5902223B2 (ja) 2016-04-13
JP6654660B2 (ja) 2020-02-26
NL301103I1 (nl) 2021-06-17
EP2063907B1 (en) 2017-08-09
CA2698595A1 (en) 2008-03-13
CY1123035T1 (el) 2021-09-14
LT3207941T (lt) 2020-04-10
CA3007075A1 (en) 2008-03-13
LTC3207941I2 (ja) 2022-10-10
ES2646545T3 (es) 2017-12-14
NL301103I2 (nl) 2021-08-02
US8470307B2 (en) 2013-06-25
HUE048356T2 (hu) 2020-07-28
US10259853B2 (en) 2019-04-16
US20220235108A1 (en) 2022-07-28
SI3207941T1 (sl) 2020-08-31
JP2024088720A (ja) 2024-07-02
JP2018135378A (ja) 2018-08-30
PT3207941T (pt) 2020-04-02
EP3520806B1 (en) 2024-03-20
HUS2100013I1 (hu) 2021-05-28
EP3207941B3 (en) 2020-08-19
JP5550905B2 (ja) 2014-07-16
EP2063907A4 (en) 2011-08-31
CA3053981A1 (en) 2008-03-13
US9181317B2 (en) 2015-11-10
JP2016155830A (ja) 2016-09-01
JP6336500B2 (ja) 2018-06-06
ES2781402T3 (es) 2020-09-01
ES2781402T7 (es) 2021-06-09
JP2014144967A (ja) 2014-08-14
US20090232767A1 (en) 2009-09-17
PL2063907T3 (pl) 2018-06-29
AU2007293047B2 (en) 2014-01-09
EP2063907A2 (en) 2009-06-03
DK3207941T3 (da) 2020-03-30
US20180022788A1 (en) 2018-01-25
US20130315860A1 (en) 2013-11-28
CA2923381A1 (en) 2008-03-13
CY1119654T1 (el) 2019-07-10
DK3207941T6 (da) 2020-11-09
LUC00206I2 (ja) 2022-10-07
EP3520806A1 (en) 2019-08-07
FR21C1017I1 (ja) 2021-07-02

Similar Documents

Publication Publication Date Title
FR21C1017I2 (fr) Procédés et compositions à base de conjugués de toxine interleukine 3 de diphtérie
FR20C1049I1 (fr) Formulations à base de triazinone et de fer
CY2018013I1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
DK2032606T3 (da) Antistoffer og immunkonjugater og anvendelser deraf
DK2444807T3 (da) Mono- og dinitropyrazolhaptenkonjugater
ATE523524T1 (de) Antikörper und immunkonjugate gegen tat226
DE602005013968D1 (de) Polyorganosiloxan und härtbare zusammensetzung daraus
IL189245A0 (en) Interleukin-1 conjugates and uses thereof
DK1817055T3 (da) Ovr110-antistofsammensætninger og fremgangsmåder til anvendelse heraf
DK1959948T3 (da) Levodopa prodrug-mesylat, sammensætninger deraf og anvendelser deraf
HK1117410A1 (en) Antibody-drug conjugates and their use
DK1991678T4 (da) Sammensætninger og fremgangsmåder til oligonukleotid-formuleringer
DK2059535T3 (da) Prlr-specifikt antistof og anvendelser deraf
DK1973564T3 (da) Vaccine omfattende streptococcus pneumoniae-kapselpolysaccharidkonjugat
DK2099823T4 (da) Målbindingsmiddelvarianter og anvendelser deraf
BRPI0716354A2 (pt) "composiÇço e mÉtodo"
HK1115758A1 (en) Hydrogenated block copolymer and composition thereof
DE602006021228D1 (de) Härtbare zusammensetzung für dämpfungsmaterial und dämpfungsmaterial
DK2121713T3 (da) Oligosaccharider, omfattende en aminooxygruppe, og konjugater deraf
DK1814977T3 (da) Arthrospira-baserede sammensætninger og anvendelser deraf
DK1937332T3 (da) Infusionsapparat og aktuator hertil
DK1968990T3 (da) Vandopløselig benzoazepinforbindelse og farmaceutisk sammensætning deraf
IL187479A0 (en) Antigen conjugates and uses thereof
BRPI0716706B8 (pt) composição à base de poliamida e artigo obtido por moldagem
FR2891114B1 (fr) Ensemble de presentation et de preparation de composition soufflee